Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients with Rheumatoid Arthritis

Trial Profile

A Phase 3, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients with Rheumatoid Arthritis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 30 Aug 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Baricitinib (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Registrational
  • Acronyms RA-BEYOND
  • Sponsors Eli Lilly and Company; Eli Lilly Japan
  • Most Recent Events

    • 30 May 2021 This trial has been completed in Slovenia , according to European Clinical Trials Database record.
    • 09 Mar 2021 This trial has been completed in Sweden , according to European Clinical Trials Database record.
    • 17 Nov 2020 Results of pooled analysis of data pooled from 3 studies ( RA BEGIN, RA BEAM and one ongoing long term extension (RA BEYOND) assessing long term efficacy of once daily Baricitinib in patients with active Rheumatoid arthritis who were either naive to DMARDs or who had inadequate response to MTX, published in the Rheumatology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top